- |||||||||| Targretin oral (bexarotene oral) / ReXceptor, Rituxan (rituximab) / Roche
Therapeutic challenges in the treatmnet of calcinosis in autoimmune diseases. (Poster Area) - Aug 5, 2024 - Abstract #EADV2024EADV_2459;
Here, we present a case of successful use of a method involving PRP and STS injections. Due to the fact that the beneficial effect of described above treatment among patients with dermatomyositis remains poorly documented in the literature, further research and standardization of the procedure are needed.
- |||||||||| Rituxan (rituximab) / Roche
In Focus: Pemphigus Vegetans - A Rare Dermatological Puzzle Explored (Poster Area) - Aug 5, 2024 - Abstract #EADV2024EADV_2451;
Early recognition and prompt initiation of appropriate immunosuppressive therapy are crucial for achieving remission and preventing disease complications. Further research is warranted to elucidate the underlying pathophysiological mechanisms and explore novel therapeutic approaches for pemphigus vegetans.
- |||||||||| Rituxan (rituximab) / Roche
Efficacy and Safety of Low-dose Corticosteroids as Maintenance Therapy in Pemphigus Vulgaris, A Randomized Trial (Poster Area) - Aug 5, 2024 - Abstract #EADV2024EADV_2449;
Despite the promising effect of rituximab in treating pemphigus, many patients still need a minimal systemic corticosteroid (CS) dose to control the disease...In the tapering group, the prednisolone dose was decreased to zero in 3-4 months, while the maintenance group had a minimal prednisone dose (<10mg/day)... Overall, maintaining a minimal dosage of CS may offer more prolonged remission with minimal side effects.
- |||||||||| Stevens-Johnson syndrome to immune checkpoint inhibitors in a patient with metastatic melanoma (Poster Area) - Aug 5, 2024 - Abstract #EADV2024EADV_2019;
Almost four years laternew metastasis occured in the sternoclavicular joint and in the lungs, and the BRAF/MEK therapy was switched toimmune checkpoint inhibitors nivolumab plus ipilimumab... In summary, patient had Stevens-Johnson syndrome including severe cutaneous and systemicadverse reactions to second line treatment therapy with anti-PD-1 antibody nivolumab plus anti-CTLA-4 antibodyipilimumab for metastatic nodular melanoma which required immediate discontinuation of immune checkpointinhibitors and rapid parenteral administration of corticosteroids in high doses.EADV Congress 2024, Amsterdam25 SEPTEMBER - 28 SEPTEMBER 2024POWERED BY M-ANAGE.COM
- |||||||||| Kisqali (ribociclib) / Novartis
Ribociclib-Associated Vitiligo: A Rare Dermatological Side Effect of Cancer Therapy (Poster Area) - Aug 5, 2024 - Abstract #EADV2024EADV_2015;
CDK4/6 inhibitors represent a promising therapeutic avenue for breast cancer patients, albeit with associated cutaneous adverse effects such as vitiligo-like lesions, as evidenced by limited cases in literature. Further studies are needed to explore the correlation between the occurrence of these adverse effects and the positive treatment response in patients.
- |||||||||| Rituxan (rituximab) / Roche
Evaluation of the adverse effects of rituximab in the management of pemphigus (Poster Area) - Aug 5, 2024 - Abstract #EADV2024EADV_1977;
National multicenter and prospective studies have evaluated its efficacy, but no studies have evaluated its long-term tolerance. Therefore, there is a need to conduct larger prospective studies to evaluate its long-term tolerance in the treatment of pemphigus
- |||||||||| Keytruda (pembrolizumab) / Merck (MSD)
Generalized bullous lichen planus secondary to pembrolizumab for advanced melanoma: A case report (Poster Area) - Aug 5, 2024 - Abstract #EADV2024EADV_1968;
The widespread use of immune-checkpoint inhibitors like pembrolizumab in cancer treatment has led to an increase in immune-related adverse effects, including dermatological reactions such as bullous lichen planus. Our case highlights the importance of recognizing and managing these rare complications during ICI therapy in a multidisciplinary team of dermatologists specialized in cutaneous adverse reactions to oncologic therapy, dermatopathologists and oncologists.
- |||||||||| Comirnaty (tozinameran) / Pfizer, BioNTech, Rituxan (rituximab) / Roche
Covid 19 vaccine-induced bullous pemphigoid: a case report study (Poster Area) - Aug 5, 2024 - Abstract #EADV2024EADV_1963;
Bullous Pemphigoid is a rare autoimmune disease that could be triggered by mRNA COVID-19 vaccines. It seems that rituximab can be an efficient therapy with an excellent safety profile.
- |||||||||| Keytruda (pembrolizumab) / Merck (MSD)
Pembrolizumab-induced lichen planus-like reaction with a very late onset (Poster Area) - Aug 5, 2024 - Abstract #EADV2024EADV_1962;
In the presented case, after total of 129 weeks of pembrolizumab immunotherapy, the very late onset of lichenoid skin reaction was observed and it was not associated with tumor progression. Recognizing toxicities from ICIs therapies becomes increasingly important in the context of ongoing immunotherapy.
- |||||||||| Orencia (abatacept) / BMS
Abatacept-Induced Lupus Erythematosus Tumidus (Poster Area) - Aug 5, 2024 - Abstract #EADV2024EADV_1958;
We describe a case of lupus erythematosus tumidus following the initiation of abatacept, a drug not previously associated with DILET. Discontinuation of the drug and treatment with oral CE led to complete remission of the lesions.
- |||||||||| Opdivo (nivolumab) / BMS
Asteatotic dermatitis induced by Pazopanib followed by Nivolumab in a patient with renal cancer (Poster Area) - Aug 5, 2024 - Abstract #EADV2024EADV_1952;
If the toxicity reappears the oncological therapy must be stopped, again treatment of the toxicity and the therapy must be switched to the next therapeutic line according to the guideline for the oncological disease. Our case is an example of a patient with Asteatotic dermatitis induced by Pazopanib followed by Nivolumab for treatment of renal cancer.
- |||||||||| Tremfya (guselkumab) / J&J
Guselkumab-associated bullous pemhigoid in a psoriasis patient: A case report. (Poster Area) - Aug 5, 2024 - Abstract #EADV2024EADV_1935;
Our case is an example of a patient with Asteatotic dermatitis induced by Pazopanib followed by Nivolumab for treatment of renal cancer. This case shows the rare side effect of the development of DBP in a patient being treated with guselkumab.
- |||||||||| Rituxan (rituximab) / Roche
Navigating polypharmacy in DRESS: A Case Report (Poster Area) - Aug 5, 2024 - Abstract #EADV2024EADV_1926;
This case represented a particular challenge, as 39 new medications had been initiated in the preceding weeks. The culprit drug may be further obfuscated by a delayed resolution of symptoms even after stopping the causative agent.
- |||||||||| Opdivo (nivolumab) / BMS
Nivolumab associated DRESS syndrome: A case report. (Poster Area) - Aug 5, 2024 - Abstract #EADV2024EADV_1925;
He was diagnosed as a case carcinoma of lungs with metastasis to vertebra (L3,L5,S1) while investigating for chronic paresthesia of upper and lower limb two and half months back and had received multiple medicines namely intravenous immunoglobulins , paracetamol, gabapentin, pregabalin and duloxetine, linagliptin- Metformin, a blend of PEA, genistein and daidzein, melatonin tablets, pramipexole and Zolpidem tartrate for a period of two weeks. Not applicable
- |||||||||| Padcev (enfortumab vedotin-ejfv) / Astellas, Pfizer
Enfortumab vedotin induce rapidly progressive hypertrophic Lichen planus (Poster Area) - Aug 5, 2024 - Abstract #EADV2024EADV_1920;
We present the first case of drug induced hypertrophic LP related to Enfortumab vedotin. Due to frequent cutaneous side effects and the potential lethal reaction, we suggest that patients receiving EV should be monitored closely for cutaneous side effects by a dermatologist.
- |||||||||| Keytruda (pembrolizumab) / Merck (MSD), vibostolimab (MK-7684) / Merck (MSD)
Severe lichenoid drug eruption after pembrolizumab plus vibostolimab treatment in a patient with endometrial cancer (Poster Area) - Aug 5, 2024 - Abstract #EADV2024EADV_1911;
Although there is no case of lichenoid drug eruption related to this combination therapy in the literature, cutaneous side effects such as lichenoid drug eruption related to pembrolizumab use are frequently reported. The immunological mechanism of pembrolizumab-induced lichenoid drug reactions is thought to be a T cell-mediated response.
- |||||||||| Ibrance (palbociclib) / Pfizer, Kisqali (ribociclib) / Novartis, Verzenio (abemaciclib) / Eli Lilly
Skin Toxicities with Cyclin-Dependent Kinase 4/6 Inhibitors in Breast Cancer: A Comprehensive Review (Poster Area) - Aug 5, 2024 - Abstract #EADV2024EADV_1899;
Cyclin-dependent kinase (CDK) -4/6 inhibitors (palbociclib, ribociclib, and abemaciclib) are relatively new therapeutic agents that first obtained regulatory approval for hormone receptor 1-positive and human epidermal growth factor receptor 2-negative advanced breast cancer patients who have progressed or relapsed on standard endocrine therapy. Nevertheless, other rare cutaneous adverse events occurred including vitiligo-like lesions, cutaneous lupus erythematosus, bullous skin rash, Stevens
- |||||||||| AiTan (rivoceranib) / HLB Bio Group, AiRuiKa (camrelizumab) / HLB Bio Group
P2 data, Journal, Combination therapy, Metastases: Efficacy and safety of camrelizumab, apatinib, and capecitabine combination therapy in advanced biliary tract cancer: a phase 2, nonrandomized, prospective study. (Pubmed Central) - Aug 5, 2024
P2
Mean BCVA was 0.83 (range 0.3-1.0) at baseline and 1.0 for all eyes after 12 In this trial, the combination of camrelizumab, apatinib, and capecitabine showed promising antitumor activity and manageable toxicity in patients with advanced BTC, especially in the
- |||||||||| Besponsa (inotuzumab ozogamicin) / Pfizer, UCB
Biomarker, Journal: Impact of Age on Pharmacogenomics and Treatment Outcomes of B-Cell Acute Lymphoblastic Leukemia. (Pubmed Central) - Aug 5, 2024
This study provides an overview of a unique series of clinical and treatment characteristics of pediatric patients with RCC treated with targeted therapies. Our results provide pharmacogenomic insights into age-related disparities in ALL cure rates and identify leukemia prognostic features for treatment individualization across age groups.
- |||||||||| Tecentriq (atezolizumab) / Roche
Review, Journal, Checkpoint inhibition: Immune checkpoint inhibitor-related type 1 diabetes mellitus which develops long after treatment discontinuation: a case report and review of literature. (Pubmed Central) - Aug 5, 2024
A 76-year-old woman, with no history of glucose tolerance issues, was diagnosed with lung adenocarcinoma with pleural invasion and underwent chemotherapy, including atezolizumab, an anti-programmed death-ligand 1 antibody...Therefore, it is crucial to remain vigilant for the development of ICI-related type 1 diabetes, not only during ICI administration, but also long after discontinuation. The online version contains supplementary material available at 10.1007/s13340-024-00719-4.
- |||||||||| Gazyva (obinutuzumab) / Roche, Biogen
Journal: Obinutuzumab in Refractory Membranous Nephropathy: A Case Series. (Pubmed Central) - Aug 5, 2024
Furthermore, the combined application of an LYN inhibitor with sunitinib has been shown to enhance therapeutic efficacy. Limited or missing data; risks of selection bias; or recall bias; underestimated first relapse-free survival time because of a limited follow-up period; unmonitored counts of CD19+
- |||||||||| Rituxan (rituximab) / Roche
Journal: Intravascular Large B-cell Lymphoma in a Young Southeast Asian Male With Recurrent Strokes and Pulmonary Ground Glass Opacities With a Normal Chest Radiograph. (Pubmed Central) - Aug 5, 2024
The patient received chemotherapy consisting of MR-CHOP (methotrexate, rituximab, cyclophosphamide, adriamycin, vincristine, and prednisolone), high-dose methotrexate, and intrathecal cytarabine, which led to complete remission...At the time of writing this case report, the patient is still in complete remission for three years after the initial diagnosis. As IVLBCL has a non-specific clinicoradiological presentation, it is important to suspect IVLBCL in patients with an atypical neurological and pulmonary presentation in the presence of raised serum lactate dehydrogenase
- |||||||||| Rituxan (rituximab) / Roche
Journal: Rituximab Therapy for Insulin Allergy in Type-1 Diabetes Mellitus. (Pubmed Central) - Aug 5, 2024
In refractory cases, systemic immunotherapy with rituximab can be a viable option. Practitioners should be aware that in patients with insulin allergy who fail conventional treatment, immunotherapy with rituximab can be a viable option.
- |||||||||| Tyvyt (sintilimab) / Eli Lilly
Journal: Refractory pruritus caused by sintilimab and its clinical management: A case report. (Pubmed Central) - Aug 5, 2024
By analyzing the treatment plan of this typical case of immune-related refractory pruritus after using sintilimab, this report discusses how clinical pharmacists can provide individualized treatment of patients by using their expertise and clinicians' cooperation and complementation in treating clinically difficult cases. This case report may be used as a reference in treating patients with refractory pruritus after the clinical use of sintilimab.
- |||||||||| Cablivi (caplacizumab) / Sanofi, Rituxan (rituximab) / Roche
Review, Journal: Immune thrombotic thrombocytopenic purpura: pathogenesis and novel therapies: a narrative review. (Pubmed Central) - Aug 5, 2024
The standard of care for iTTP today consists of therapeutic plasma exchange, anti-von Willebrand factor (vWF) caplacizumab, and immunosuppressives (e.g., corticosteroids and rituximab), known as the triple therapy, which has significantly reduced exacerbation and mortality rates. We hope that the information provided in the review article helps better understand the pathogenesis of iTTP, which may guide design novel and more effective therapeutics for this potentially fatal disorder.
|
